Charles River Laboratories International (CRL) is back on investor radars after recent share price moves, with the stock near US$181 and mixed returns across the past year, the past month, and the past three months.

The recent 7 day share price return of 8.81% contrasts with a year to date share price return of 10.25% and a 1 year total shareholder return of 28.52%, suggesting short term momentum is picking up after a weaker stretch.

If you are comparing Charles River Laboratories International with other opportunities in the sector, this is a good moment to scan for specialist healthcare AI stocks using the 35 healthcare AI stocks

With the share price near US$181 against an average analyst target around US$201 and an intrinsic value estimate implying less room, investors now face a key question: is there still a buying opportunity, or is future growth already priced in?

Most Popular Narrative: 42.1% Undervalued

According to the most followed valuation narrative, Charles River Laboratories International's fair value of $313.61 sits well above the recent $181.68 share price, framing a wide gap that investors will want to understand.

The acquisition of K.F. (Cambodia) by Charles River Laboratories in January 2026 is more than just another corporate transaction.

It reflects a deeper reality within the drug development ecosystem.

Want to see why this narrative points to such a large valuation gap? It leans heavily on a profit margin shift, revenue expansion and a future earnings multiple that assumes the business can support premium pricing power over time.

Result: Fair Value of $313.61 (UNDERVALUED)

However, this depends on assumptions that could fail, including pressure on NHP sourcing due to regulation or biosecurity, and any setback in profit margin expectations.

Another View: Our DCF Model Sees Limited Upside

The user narrative points to a fair value of $313.61 and a 42.1% discount, yet the SWS DCF model tells a different story. At a current price of $181.68 versus a future cash flow value estimate of $140.41, the stock screens as overvalued on this method. Which lens should you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of optimism and concern in this story, it makes sense to look at the numbers yourself and move quickly to form a balanced view by weighing the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock, you miss the bigger picture. Use the Simply Wall St Screener to quickly surface focused ideas that match your style.

• Zero in on potential value opportunities by scanning a curated set of 51 high quality undervalued stocks that may warrant a closer look on your watchlist.
• Prioritise resilience by checking out 72 resilient stocks with low risk scores that score well on risk, so you can focus your energy where the downside looks more contained.
• Get ahead of the crowd by reviewing a screener containing 23 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.